Carboplatin: calculated based on AUC=2 based on renal function, ivgtt, 120 minutes, d1, 8, every 3 weeks

An exploratory study of the efficacy and safety of the toripalimab in combination with eribulin plus carboplatin regimen in advanced triple-negative breast cancer treated with anthracyclines and taxanes

An exploratory study of the efficacy and safety of the sintilimab in combination with eribulin plus carboplatin regimen in advanced triple-negative breast cancer treated with anthracyclines and taxanes

Cadonilimab combined with gemcitabine plus carboplatin in metastatic triple-negative breast cancer: a single-arm, multicenter, phase II clinical study